Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

1074 - Is There a Difference in PFS or OS of T790M-Mutated NSCLC Patients Treated with Osimertinib either after Chemotherapy or Immediately after Previous Target Therapy?

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Targeted Therapy

Tumour Site

Presenters

Chien Hao Lai

Citation

Annals of Oncology (2018) 29 (suppl_8): viii493-viii547. 10.1093/annonc/mdy292

Authors

C.H. Lai, M. Lin, Y. Tsai, C. Wang

Author affiliations

  • Division Of Pulmonary And Critical Care Medicine, Chang Gung Memorial Hospital-Kaohsiung, 83301 - Kaohsiung city/TW
More

Resources

Abstract 1074

Background

Osimertinib (Tagresso) is recommended as an option for treating patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC whose disease has progressed after first-line TKIs. We compared OS and PFS in patients who received osimertinib treatment immediately after previous treatment with TKIs, and those who received osimertinib after their last cycle of chemotherapy.

Methods

This study enrolled a total of 2605 patients who were diagnosed with lung cancer between January 2013 and April 2017. Among these patients, there were 779 patients with inoperable EGFR-mutated NSCLC who had received TKIs as first-line therapy. Furthermore, 166 of these 779 patients who were resistant to TKIs had received re-biopsy. There were 71 patients who received osimertinib therapy for at least 2 weeks since March 2016.

Results

Demographics and clinical characteristics of the 71 patients are described in the table. Among these cases, 26 (36.6%) patients received osimertinib as 2nd-line therapy after first-line TKI therapy. Seventeen (23.9%) patients received osimertinib as 3rd-line therapy, and 28 (39.4%) patients received osimertinib in > = 4th-line setting. The median PFS in patients as 2nd-line therapy was 11.9 months and that was 17.3 months as 3rd-line therapy. The median PFS in patients as > = 4th-line therapy was 9.3 months. Among the 71 patients, there were 34 (47.9%) patients who received it after previous chemotherapy (Group A), and 37 patients (52.1%) who received osimertinib immediately after previous TKI therapy (Group B). The median PFS for Group A and Group B patients was 12.8 months and 11.0 months, respectively (p = 0.306). A higher percentage of patients in Group B had progressive disease (8 cases, 21.6%) compared to Group A (2 case, 5.9% ; χ2 = 0.08). Besides, obesity patients (BMI > = 27) had trend of shorter PFS with osimertinib therapy. (8.4 months vs. 12.6 months, P = 0.05).

Conclusions

Our data suggested that T790M-mutated NSCLC patients may have a better response, and longer PFS when treated with osimertinib therapy after previous chemotherapy compared to after previous TKI treatment. Due to the small sample size, our data need to be updated and need further re-analysis.

Clinical trial identification

Legal entity responsible for the study

Chien-Hao Lai; Chin-Chou Wang.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.